Community-acquired pneumonia

Current Opinion in Pulmonary Medicine

Volumn 19, Issue 3, 2013, Pages 198-208

  Irfan, Muhammad ^a   Farooqi, Joveria ^b   Hasan, Rumina ^b  

^a AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

^b AGA KHAN UNIVERSITY   (Pakistan)

Author keywords

Aetiology; Antimicrobial therapy; Biomarkers; Community acquired pneumonia; Diagnosis; Severity assessment tools; Severity index

Indexed keywords

AMANTADINE; AMINOGLYCOSIDE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CARBAPENEM; CEFEPIME; CEFTAROLINE FOSAMIL; CEPHALOSPORIN; CIPROFLOXACIN; CLAVULANIC ACID; CORTICOSTEROID; DOXYCYCLINE; GAMMA INTERFERON; INACTIVATED VACCINE; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MEROPENEM; MOXIFLOXACIN; OSELTAMIVIR; PIPERACILLIN PLUS TAZOBACTAM; PNEUMOCOCCUS VACCINE; PROADRENOMEDULLIN; RIMANTADINE; TEICHOIC ACID; TETRACYCLINE; TIGECYCLINE; TUMOR NECROSIS FACTOR ALPHA; VANCOMYCIN; ZANAMIVIR;

ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BLOOD CULTURE; CHLAMYDIA; COMMUNITY ACQUIRED PNEUMONIA; CORTICOSTEROID THERAPY; COXIELLA BURNETII; DISEASE SEVERITY; DRUG MEGADOSE; EARLY DIAGNOSIS; GRAM STAINING; HAEMOPHILUS INFLUENZAE; HEALTH CARE NEED; HIGH RISK POPULATION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; INFECTION RISK; KLEBSIELLA PNEUMONIAE; LEGIONELLA PNEUMOPHILA; LEUKOCYTE COUNT; LIFE EXPECTANCY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MICROARRAY ANALYSIS; MIXED INFECTION; MONOTHERAPY; MORBIDITY; MORTALITY; MYCOPLASMA PNEUMONIAE; OUTPATIENT CARE; PLEURA FLUID; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PROGNOSIS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SPUTUM ANALYSIS; STREPTOCOCCUS PNEUMONIAE; SUPERINFECTION; TREATMENT DURATION; VIRUS PNEUMONIA;

COMMUNITY-ACQUIRED INFECTIONS; HUMANS; PNEUMONIA; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 84878111835     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e32835f1d12     Document Type: Review

References (100)

1. Welte T, Torres A, Nathwani D. Clinical and economic burden of communityacquired pneumonia among adults in Europe. Thorax 2012; 67:71-79.
2. Wiemken TL, Peyrani P, Ramirez JA. Global changes in the epidemiology of community-acquired pneumonia. Semin Respir Crit Care Med 2012; 33:213-219.
3. Eurich DT, Majumdar SR, Marrie TJ. Population-based cohort study of outpatients with pneumonia: rationale, design and baseline characteristics. BMC Infect Dis 2012; 12:135.
4. Haessler S, Schimmel JJ. Managing community-acquired pneumonia during flu season. Cleve Clin J Med 2012; 79:67-78.
5. Postma DF, van Werkhoven CH, Huijts SM, et al. New trends in the prevention and management of community-acquired pneumonia. Neth J Med 2012; 70:337-348.
6. Capelastegui A, Espana PP, Bilbao A, et al. Etiology of community-acquired pneumonia in a population-based study: Link between etiology and patients characteristics, process-of-care, clinical evolution and outcomes. BMC Infect Dis 2012; 12:134.
7. Huijskens EG, van Erkel AJ, Palmen FM, et al. Viral and bacterial aetiology of community-acquired pneumonia in adults. Influenza Other Respi Viruses 2012. doi: 10.1111/j.1750-2659.2012.00425. [Epub ahead of print]
8. Marekovic I, Plecko V, Boras Z, et al. Value of rapid aetiological diagnosis in optimization of antimicrobial treatment in bacterial community acquired pneumonia. Coll Antropol 2012; 36:401-408.
9. Cilloniz C, Ewig S, Polverino E, et al. Community-acquired pneumonia in outpatients: aetiology and outcomes. Eur Respir J 2012; 40:931- 938.
10. Sangil A, Calbo E, Robles A, et al. Aetiology of community-acquired pneumonia among adults in an H1N1 pandemic year: the role of respiratory viruses. Eur J Clin Microbiol Infect Dis 2012; 31:2765-2772.
11. Tao LL, Hu BJ, He LX, et al. Etiology and antimicrobial resistance of community-acquired pneumonia in adult patients in China. Chin Med J (Engl) 2012; 125:2967-2972.
12. Aoyagi T, Yamada M, Kunishima H, et al. Characteristics of infectious diseases in hospitalized patients during the early phase after the 2011 Great East Japan earthquake: pneumonia as a significant reason for hospital care. Chest 2012; doi: 10.1378/chest.11-3298. [Epub ahead of print]
13. Kreienbuehl L, Charbonney E, Eggimann P. Community-acquired necrotizing pneumonia due to methicillin-sensitive Staphylococcus aureus secreting Panton-Valentine leukocidin: a review of case reports. Ann Intensive Care 2011; 1:52; doi:10.1186/2110-5820-1-52.
14. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Prevalence of methicillinresistant staphylococcus aureus as an etiology of community-acquired pneumonia. Clin Infect Dis 2012; 54:1126-1133.
15. Cilloniz C, Ewig S, Menendez R, et al. Bacterial co-infection with H1N1 infection in patients admitted with community acquired pneumonia. J Infect 2012; 65:223-230.
16. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336:243-250.
17. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58:377-382.
18. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 (Suppl 2):S27-S72.
19. Espana PP, Capelastegui A, Quintana JM, et al. A prediction rule to identify allocation of inpatient care in community-acquired pneumonia. Eur Respir J 2003; 21:695-701.
20. Charles PG, Wolfe R, Whitby M, et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis 2008; 47:375-384.
21. Espana PP, Capelastegui A, Gorordo I, et al. Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am J Respir Crit Care Med 2006; 174:1249-1256.
22. Buising KL, Thursky KA, Black JF, et al. Identifying severe communityacquired pneumonia in the emergency department: a simple clinical prediction tool. Emerg Med Australas 2007; 19:418-426.
23. Renaud B, Labarere J, Coma E, et al. Risk stratification of early admission to the intensive care unit of patients with no major criteria of severe communityacquired pneumonia: development of an international prediction rule. Crit Care 2009; 13:R54; doi: 10.1186/cc7781.
24. Rello J, Rodriguez A, Lisboa T, et al. PIRO score for community-acquired pneumonia: a new prediction rule for assessment of severity in intensive care unit patients with community-acquired pneumonia. Crit Care Med 2009; 37:456-462.
25. Chalmers JD, Taylor JK, Mandal P, et al. Validation of the Infectious Diseases Society of America/American Thoratic Society minor criteria for intensive care unit admission in community-acquired pneumonia patients without major criteria or contraindications to intensive care unit care. Clin Infect Dis 2011; 53:503-511.
26. Robins-Browne KL, Cheng AC, Thomas KA, et al. The SMART-COP score performs well for pneumonia risk stratification in Australia's Tropical Northern Territory: a prospective cohort study. Trop Med Int Health 2012; 17:914- 919.
27. Chalmers JD, Mandal P, Singanayagam A, et al. Severity assessment tools to guide ICU admission in community-acquired pneumonia: systematic review and meta-analysis. Intensive Care Med 2011; 37:1409-1420.
28. Labarere J, Schuetz P, Renaud B, et al. Validation of a clinical prediction model for early admission to the intensive care unit of patients with pneumonia. Acad Emerg Med 2012; 19:993-1003.
29. Pereira JM, Paiva JA, Rello J. Severe sepsis in community-acquired pneumonia: early recognition and treatment. Eur J Intern Med 2012; 23:412-419.
30. Carbonara S, Monno L, Longo B, Angarano G. Community-acquired pneumonia. Curr Opin Pulm Med 2009; 15:261-273.
31. Akram AR, Chalmers JD, Hill AT. Predicting mortality with severity assessment tools in out-patients with community-acquired pneumonia. QJM 2011; 104:871-879.
32. Waterer GW, Rello J, Wunderink RG. Management of community-acquired pneumonia in adults. Am J Respir Crit Care Med 2011; 183:157-164.
33. Watkins RR, Lemonovich TL. Diagnosis and management of communityacquired pneumonia in adults. Am Fam Physician 2011; 83:1299-1306.
34. Levy ML, Le Jeune I, Woodhead MA, et al. Primary care summary of the British Thoracic Society Guidelines for the management of community acquired pneumonia in adults: 2009 update. Endorsed by the Royal College of General Practitioners and the Primary Care Respiratory Society UK. Prim Care Respir J 2010; 19:21-27.
35. Blasi F, Bocchino M, Di Marco F, et al. The role of biomarkers in low respiratory tract infections. Eur J Intern Med 2012; 23:429-435.
36. Lacoma A, Rodriguez N, Prat C, et al. Usefulness of consecutive biomarkers measurement in the management of community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2012; 31:825-833.
37. Berg P, Lindhardt BO. The role of procalcitonin in adult patients with community-acquired pneumonia: a systematic review. Dan Med J 2012; 59:A4357.
38. Lippi G, Meschi T, Cervellin G. Inflammatory biomarkers for the diagnosis, monitoring and follow-up of community-acquired pneumonia: clinical evidence and perspectives. Eur J Intern Med 2011; 22:460-465.
39. Renaud B, Schuetz P, Claessens YE, et al. Proadrenomedullin improves REA-ICU score for predicting early severe community-acquired pneumonia. Chest 2012; doi: 10.1378/chest.11-2574. [Epub ahead of print]
40. Bello S, Lasierra AB, Minchole E, et al. Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology. Eur Respir J 2012; 39:1144-1155.
41. Courtais C, Kuster N, Dupuy AM, et al. Proadrenomedullin, a useful tool for risk stratification in high pneumonia severity index score community acquired pneumonia. Am J Emerg Med 2013; 31:215-221.
42. Albrich WC, Dusemund F, Ruegger K, et al. Enhancement of CURB65 score with proadrenomedullin (CURB65-A) for outcome prediction in lower respiratory tract infections: derivation of a clinical algorithm. BMC Infect Dis 2011; 11:112.
43. Huang DT, Angus DC, Kellum JA, et al. Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia. Chest 2009; 136 : 823-831.
44. Chalupa P, Beran O, Herwald H, et al. Evaluation of potential biomarkers for the discrimination of bacterial and viral infections. Infection 2012; 39:411-417.
45. Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral pneumonia. Lancet 2011; 377:1264-1275.
46. Menendez R, Sahuquillo-Arce JM, Reyes S, et al. Cytokine activation patterns and biomarkers are influenced by microorganisms in community-acquired pneumonia. Chest 2012; 141:1537-1545.
47. Horie M, Ugajin M, Suzuki M, et al. Diagnostic and prognostic value of procalcitonin in community-acquired pneumonia. Am J Med Sci 2012; 343:30-35.
48. File TM Jr. New diagnostic tests for pneumonia: what is their role in clinical practice? Clin Chest Med 2011; 32:417-430.
49. Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009; 302:1059- 1066.
50. Polverino E, Torres Marti A. Community-acquired pneumonia. Minerva Anestesiol 2011; 77:196-211.
51. Vernet G, Saha S, Satzke C, et al. Laboratory-based diagnosis of pneumococcal pneumonia: state of the art and unmet needs. Clin Microbiol Infect 2011; 17 (Suppl 3):1-13.
52. Ustianowski A. Diagnostics for community-acquired and atypical pneumonia. Curr Opin Pulm Med 2012; 18:259-263.
53. Zhang L, Zong ZY, Liu YB, et al. PCR versus serology for diagnosing Mycoplasma pneumoniae infection: a systematic review & meta-analysis. Indian J Med Res 2011; 134:270-280.
54. Yin YD, Zhao F, Ren LL, et al. Evaluation of the Japanese Respiratory Society guidelines for the identification of Mycoplasma pneumoniae pneumonia. Respirology 2012; 17:1131-1136.
55. Wegdam-Blans MC, Wielders CC, Meekelenkamp J, et al. Evaluation of commonly used serological tests for detection of Coxiella burnetii antibodies in well defined acute and follow-up sera. Clin Vaccine Immunol 2012; 19:1110-1115.
56. Xu D, Li S, Chen Z, Du L. Detection of Mycoplasma pneumoniae in different respiratory specimens. Eur J Pediatr 2011; 170:851-858.
57. Bartlett JG. Diagnostic tests for agents of community-acquired pneumonia. Clin Infect Dis 2011; 52 (Suppl 4):S296-S304.
58. Cho MC, Kim H, An D, et al. Comparison of sputum and nasopharyngeal swab specimens for molecular diagnosis of Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella pneumophila. Ann Lab Med 2012; 32:133-138.
59. Benitez AJ, Thurman KA, Diaz MH, et al. Comparison of real-time PCR and a microimmunofluorescence serological assay for detection of Chlamydophila pneumoniae infection in an outbreak investigation. J Clin Microbiol 2012; 50:151-153.
60. Vu HT, Yoshida LM, Suzuki M, et al. Association between nasopharyngeal load of Streptococcus pneumoniae, viral coinfection, and radiologically confirmed pneumonia in Vietnamese children. Pediatr Infect Dis J 2011; 30:11-18.
61. Tham N, Hang V, Khanh TH, et al. Comparison of the Roche Real Time ready Influenza A/H1N1 detection set with CDC A/H1N1pdm09 RT-PCR on samples from three hospitals in Ho Chi Minh City, Vietnam. Diagn Microbiol Infect Dis 2012; 74:131-136.
62. Xiao D, Zhao F, Lv M, et al. Rapid identification of microorganisms isolated from throat swab specimens of community-acquired pneumonia patients by two MALDI-TOF MS systems. Diagn Microbiol Infect Dis 2012; 73:301-307.
63. Tanner H, Boxall E, Osman H. Respiratory viral infections during the 2009- 2010 winter season in Central England, UK: incidence and patterns of multiple virus co-infections. Eur J Clin Microbiol Infect Dis 2012; 31:3001-3006.
64. Wiersinga WJ, Bonten MJ, Boersma WG, et al. SWAB/NVALT (Dutch Working Party on Antibiotic Policy and Dutch Association of Chest Physicians) guidelines on the management of community-acquired pneumonia in adults. Neth J Med 2012; 70:90-101.
65. Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64 (Suppl 3):iii1-iii55.
66. Bradley JS, Byington CL, Shah SS, et al. The management of communityacquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011; 53:e25-e76.
67. Harris M, Clark J, Coote N, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax 2011; 66 (Suppl 2):ii1-iii23.
68. Okada F, Ando Y, Nakayama T, et al. Pulmonary thin-section CT findings in acute Moraxella catarrhalis pulmonary infection. Br J Radiol 2011; 84:1109- 1114.
69. Bartziokas K, Daenas C, Preau S, et al. Vibration response imaging: evaluation of rater agreement in healthy subjects and subjects with pneumonia. BMC Med Imaging 2010; 10:6; doi:10.1186/1471-2342-10-6.
70. Shiley KT, Van Deerlin VM, Miller WT Jr. Chest CT features of communityacquired respiratory viral infections in adult inpatients with lower respiratory tract infections. J Thorac Imaging 2010; 25:68-75.
71. Reissig A, Gramegna A, Aliberti S. The role of lung ultrasound in the diagnosis and follow-up of community-acquired pneumonia. Eur J Intern Med 2012; 23:391-397.
72. Niederman MS, Luna CM. Community-acquired pneumonia guidelines: a global perspective. Semin Respir Crit Care Med 2012; 33:298-310.
73. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections: full version. Clin Microbiol Infect 2011; 17 (Suppl 6):E1-E59.
74. Gupta D, Agarwal R, Aggarwal AN, et al. Guidelines for diagnosis and management of community- and hospital-acquired pneumonia in adults: Joint ICS/NCCP(I) recommendations. Lung India 2012; 29:S27-S62.
75. Nair GB, Niederman MS. Community-acquired pneumonia: an unfinished battle. Med Clin North Am 2011; 95:1143-1161.
76. Eliakim-Raz N, Robenshtok E, Shefet D, et al. Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults. Cochrane Database Syst Rev 2012; 9:CD004418; doi: 10.1002/14651858.CD004418. pub4.
77. Rodrigo C, McKeever TM, Woodhead M, Lim WS. Single versus combination antibiotic therapy in adults hospitalised with community acquired pneumonia. Thorax 2012. doi:10.1136/thoraxjnl-2012-202296. [Epub ahead of print]
78. Ewig S, Hecker H, Suttorp N, et al. Moxifloxacin monotherapy versus betalactam mono- or combination therapy in hospitalized patients with community-acquired pneumonia. J Infect 2011; 62:218-225.
79. Kwong JC, Chua K, Charles PG. Managing severe community-acquired pneumonia due to community methicillin-resistant Staphylococcus aureus (MRSA). Curr Infect Dis Rep 2012; 14:330-338.
80. Menendez R, Torres A, Reyes S, et al. Initial management of pneumonia and sepsis:factors associated with improved outcome. Eur Respir J 2012; 39:156- 162.
81. Bader MS, Abouchehade KA, Yi Y, et al. Antibiotic administration longer than eight hours after triage and mortality of community-acquired pneumonia in patients with diabetes mellitus. Eur J Clin Microbiol Infect Dis 2011; 30:881-886.
82. File TM Jr, Low DE, Eckburg PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 2010; 51:1395-1405.
83. Bergallo C, Jasovich A, Teglia O, et al. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn Microbiol Infect Dis 2009; 63:52-61.
84. Tanaseanu C, Milutinovic S, Calistru PI, et al. Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia. BMC Pulm Med 2009; 9:44; doi:10.1186/1471-2466-9-44.
85. Cai Y, Wang R, Liang B, et al. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother 2011; 55:1162-1172.
86. Debellis HF, Jones MC, Kincaid SE. An update for community-acquired bacterial pneumonia pharmacotherapy: what's new and where does it fit? J Pharm Pract 2012; 25: 569-575.
87. Snijders D, Daniels JM, de Graaff CS, et al. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med 2010; 181:975-982.
88. Fernandez-Serrano S, Dorca J, Garcia-Vidal C, et al. Effect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trial. Crit Care 2011; 15:R96; doi:10.1186/cc10103.
89. Meijvis SC, Hardeman H, Remmelts HH, et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 377:2023-2030.
90. Salluh JI, Soares M, Coelho LM, et al. Impact of systemic corticosteroids on the clinical course and outcomes of patients with severe community-acquired pneumonia: a cohort study. J Crit Care 2011; 26:193-200.
91. Povoa P, Salluh JI. What is the role of steroids in pneumonia therapy? Curr Opin Infect Dis 2012; 25: 199-204.
92. Kim SH, Hong SB, Yun SC, et al. Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores. Am J Respir Crit Care Med 2011; 183:1207-1214.
93. Brun-Buisson C, Richard JC, Mercat A, et al. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am J Respir Crit Care Med 2011; 183:1200-1206.
94. Zhang Y, Fang C, Dong BR, et al. Oxygen therapy for pneumonia in adults. Cochrane Database Syst Rev 2012; 3:CD006607; doi:10.1002/14651858.CD006607.pub4.
95. Harper SA, Bradley JS, Englund JA, et al. Seasonal influenza in adults and children: diagnosis, treatment, chemoprophylaxis, and institutional outbreak management - clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1003-1032.
96. ACIP. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61:816-819.
97. ACIP. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1-64.
98. ACIP. Prevention and control of influenza with vaccines : recommendationsofthe Advisory Committee on Immunization Practices (ACIP): United States, 2012- 13 influenza season. MMWR Morb Mortal Wkly Rep 2012; 61:613-618.
99. Jamieson DJ, Kissin DM, Bridges CB, Rasmussen SA. Benefits of influenza vaccination during pregnancy for pregnant women. Am J Obstet Gynecol 2012; 207:S17-S20.
100. Mannino S, Villa M, Apolone G, et al. Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy. Am J Epidemiol 2012; 176:527-533.